Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomatrix (BXM) Looking Great -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (251)	11/29/1997 6:04:00 AM
From: James Baker	Read Replies (1) \| Respond to of 569

John, That abstract is a very nice find. I agree the results are very good. The 8 month interval is a duel edged sword IMO. It implies that injections could be given at this inverval for a large percentage of patients decreasing their cost and making SYNVISC a much better treatment on a cost/benefit ratio with NSAIDS. 3 injectios series (of 3 inections each time) would work for 24 months. ie the annual cost is $1500/2 = $750 not the $1000 we have thought. (Cheap NSAIDS can cost $600 per yr and the expensive ones over $1200 per yr - medication only, not treatment of previously discussed side effects) The corporate downside is that the decreased sales per patient MUST be made up by good patient RP, word of mouth advertising and physician acceptance of this noteworthy treatment. Interesting difference in swelling reaction depending on medial vs lateral injection. I don't know if stat signif but if so this knowledge widely distributed could cut reactions in half. All to the good of patient and SYNVISC. Market comment: It looks like all the BIOMATRIX supporters took Friday off. Volume was nothing and the MM just let it drift on down. Would expect some bargin hunting on Monday. Jim

To: John McCarthy who wrote (251)	11/29/1997 8:27:00 AM
From: John McCarthy	Read Replies (1) \| Respond to of 569

Forbes Article ..............................10/20/97 Analysts project Biomatrix sales of $100 million in 1999 and $175 million in the year 2000. This is clearly a remarkable target for a company with sales of just $5 million in 1996. Two similar products exist. One of them, Hyalgan, from Italy's Fidea Pharmaceutical, already has FDA approval. Biomatrix's technical advantage lies in the greater viscosity of its fluid, achieved through a patented chemical process. A speculative buy on dips to $34. FYI: forbes.com Regards, John